Literature DB >> 30996258

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Peng Liu1,2,3,4,5,6, Liwei Zhao1,2,3,4,5,6, Jonathan Pol2,3,4,5,6, Sarah Levesque1,2,3,4,5,6, Adriana Petrazzuolo1,2,3,4,5,6, Christina Pfirschke7, Camilla Engblom7,8, Steffen Rickelt9, Takahiro Yamazaki10, Kristina Iribarren2,3,4,5,6, Laura Senovilla2,3,4,5,6, Lucillia Bezu1,2,3,4,5,6,11, Erika Vacchelli2,3,4,5,6, Valentina Sica2,3,4,5,6, Andréa Melis12,13, Tiffany Martin12,13, Lin Xia14,15, Heng Yang14,15, Qingqing Li14,15, Jinfeng Chen14,15, Sylvère Durand2,3,4,5,6, Fanny Aprahamian2,3,4,5,6, Deborah Lefevre2,3,4,5,6, Sophie Broutin16, Angelo Paci16,17, Amaury Bongers16, Veronique Minard-Colin18, Eric Tartour19,20, Laurence Zitvogel1,15,18,21,22, Lionel Apetoh12,13, Yuting Ma14,15, Mikael J Pittet7,23, Oliver Kepp24,25,26,27,28,29, Guido Kroemer30,31,32,33,34,35,36,37.   

Abstract

The original version of this Article contained an error in the spelling of the author Lin Xia, which was incorrectly given as Xia Lin. This has now been corrected in both the PDF and HTML versions of the Article.

Entities:  

Year:  2019        PMID: 30996258      PMCID: PMC6470160          DOI: 10.1038/s41467-019-09838-y

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


Correction to: Nature Communications 10.1038/s41467-019-09415-3, published online 2 April 2019 The original version of this Article contained an error in the spelling of the author Lin Xia, which was incorrectly given as Xia Lin. This has now been corrected in both the PDF and HTML versions of the Article.
  2 in total

1.  A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.

Authors:  Hiroaki Tachi; Kengo Nishino; Taisuke Nakaizumi; Kenya Kuramoto; Kei Shimizu; Yusuke Yamamoto; Keisuke Kobayashi; Hideo Ichimura; Akiko Sakata; Takeshi Nawa
Journal:  Thorac Cancer       Date:  2020-05-20       Impact factor: 3.500

2.  Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.

Authors:  Annunziata Nigro; Luca Ricciardi; Ilaria Salvato; Francesco Sabbatino; Monica Vitale; Maria Assunta Crescenzi; Barbara Montico; Massimo Triggiani; Stefano Pepe; Cristiana Stellato; Vincenzo Casolaro; Jessica Dal Col
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.